Catalpol: A potential therapeutic for neurodegenerative diseases

Current Medicinal Chemistry

Volumn 22, Issue 10, 2015, Pages 1278-1291

  Jiang, B ^a   Shen, R F ^a   Bi, J ^a   Tian, X S ^b   Hinchliffe, T ^b   Xia, Y ^b  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Catalpol; Inflammation; Mitochondria; Neurodegenerative disease; Neuroprotection; Neurotrophins; NF B; Oxidant stress

Indexed keywords

CASPASE; CATALPOL; NEUROTROPHIN; NITRIC OXIDE; IRIDOID; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANGIOSPERM; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN HYPOXIA; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN MITOCHONDRION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIFE EXPECTANCY; MICROGLIA; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PLANT ROOT; REHMANNIA GLUTINOSA; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; ISOLATION AND PURIFICATION; NEURODEGENERATIVE DISEASES; REHMANNIA;

ANIMALS; HUMANS; IRIDOID GLUCOSIDES; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; REHMANNIA;

EID: 84931264877     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150114151720     Document Type: Article

References (140)

1. Borroni, B.; Premi, E.; Bozzali, M.; Padovani, A. Reserve mechanisms in neurodegenerative diseases: from bench to bedside and back again. Curr. Med. Chem., 2012, 19(36), 6112-6118.
2. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
3. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physi. Rev., 2001, 81(2), 741-766.
4. Ulusoy, A.; Di Monte, D.A. Alpha-synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mo. Neurobiol., 2013, 47(2), 484-494.
5. O'Brien, J.T.; Burns, A. Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology. J. Psychopharm., 2011, 25(8), 997-1019.
6. Abou-Sleiman, P.M.; Muqit, M.M.; Wood, N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci., 2006, 7(3), 207-219.
7. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol., 2010, 9(7), 702.
8. Zhang, H.Y.; Tang, X.C. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol. Sci., 2006, 27(12), 619.
9. Jame, L. Natural product-derived treatments of neuropsychiatric disorders: review of progress and recommendations. Stud. Nat. Prod. Chem., 2000, 24, 1093-1137.
10. Rainer, M.; Mucke, H.; Schlaefke, S. Ginkgo biloba extract EGb 761A (R) in the treatment of dementia: A pharmacoeconomic analysis of the Austrian setting. Wien. Klin. Wochen., 2013, 125(1-2), 8-15.
11. Wang, R.;Yan, H. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine1. Acta Pharmaco. Sin., 2006, 27(1), 1-26.
12. Cui, Y.; Yan, Z.; Hou, S.; Chang, Z. Effect of radix rehmanniae preparata on the expression of c-fos and NGF in hippocampi and learning and memory in rats with damaged thalamic arcuate nucleus. J. Chin. Med. Mater., 2004, 27(8), 589.
13. Zhou, J.Z.; Zhang, Y.X.; Zhou, J.H. Cognition-enhancing effect of Liu Wei Dihuang Decoction on age-related deterioration of learning and memory in senescence-accelerated mouse (SAM). Chin. J. Exp. Tradit. Med. Form., 1999, 5(4), 29-33.
14. Holmes, P. Jade remedies: A Chinese herbal reference for the West.; Snow Lotus Press, 1992.
15. Yen, K.Y. The illustrated Chinese materia medica: crude and prepared. SMC Pub, 1992.
16. Zhao, J.S.; Ye, Z.B.; Zhao, Y.; Chen, J.J.; Zhong, J.G.;Wang, L. Clinical and pathological experimental study on deferring senile effects of Liuwei Dihuang Pill. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica, 2006, 8(2), 117-122.
17. Foster, S.; Yue, C.X. Herbal emissaries.; Healing Arts Press: Rochester( VT), 1992.
18. Wang, Y.S. Pharmacology and Applications of Chinese Materia Medica.; People's Health Publisher: Beijing, 1983.
19. Zhu, Y.P. Chinese materia medica: chemistry, pharmacology and applications. CRC PressI Llc., 1998.
20. Zhang, X.L.; Jiang, B.; Wang, J.Y.; An, L.J. Comparison of techniques for the extraction of the neuroprotective drug catalpol from Rehmannia glutinosa Libosch. J. Biotechnol., 2008, 136, S471.
21. Wang, J.H.; Zhang, R.; Hu, Y.E.; Xia, Z.Q. Effect of catalpol from Radix Rehmanniae on A25-35-induced apoptosis of PC12 cells. J. Shanghai Jiaotong University (Medical Science), 2007, 7, 14.
22. Jiang, B.; Du, J.; Liu, J.H.; Bao, Y.M.; An, L.J. Catalpol attenuates the neurotoxicity induced by -amyloid (1-42) in cortical neuronglia cultures. Brain Res., 2008, 1188(10), 139-147.
23. Liang, J.H.; Du, J.; Hao, S.; Bi, J.; Jiang, T.; Xu, L.D.; Jiang. B. Catalpol protects primary cultured cortical neurons induced by A1-42 through a mitochondrial-dependent caspase pathway. Neurochem. Iint., 2009, 55(8), 741-746.
24. Liu, S.; Hu, Y.E.; Xia, Z.Q. Changes of memory and M receptor injection of A-(25-35) into basal ganglion region of forebrain and effect of catalpol. J. Shanghai Jiaotong University (Medical Science), 2007, 8, 17.
25. Wang, Z.; Liu, Q.; Zhang, R.; Liu, S.; Xia, Z.; Hu, Y. Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors. Neuroscience, 2009, 163(4), 1363-1372.
26. Xia, Z.M.; Zhang, R.; Wu, P.P.; Xia, Z.Q.; Hu, Y.E. Memory defect induced by beta-amyloid plus glutamate receptor agonist is alleviated by catalpol and donepezil through different mechanisms. Brain Res., 2012, 1441, 27-37.
27. Bi, J.; Wang, X.B.; Chen, L.; Hao, S.; An, L.J.; Jiang, B.; Guo, L. Catalpol protects mesencephalic neurons against MPTP induced neurotoxicity via attenuation of mitochondrial dysfunction and MAO-B activity. Toxicolin. Vitro, 2008, 22(8), 1883-1889.
28. Jiang, B.; Zhang, H.; Bi, J.; Zhang, X.L. Neuroprotective activities of catalpol on MPP+/MPTP-induced neurotoxicity. Neurol. Res., 2008, 30(6), 639-644.
29. Bi, J.; Jiang, B.; Hao, S.; Zhang, A.H.; Dong, Y.S.; Jiang, T.; An, L.J. Catalpol attenuates nitric oxide increase via ERK signaling pathways induced by rotenone in mesencephalic neurons. Neurochem. int., 2009, 54(3), 264-270.
30. Tian, Y.Y.; Jiang, B.; An, L.J.; Bao, Y.M. Neuroprotective effect of catalpol against MPP+-induced oxidative stress in mesencephalic neurons. Eur. J. Pharmacol., 2007, 568(1), 142-148.
31. Mao, Y.R.; Jiang, L.; Duan, Y.L.; An, L.J.; Jiang, B. Efficacy of catalpol as protectant against oxidative stress and mitochondrial dysfunction on rotenone-induced toxicity in mice brain. Environ. Toxicol. Pha., 2007, 23(3), 314-318.
32. Xu, G.; Xiong, Z.; Yong, Y.; Wang, Z.; Ke, Z.; Xia, Z.; Hu, Y. Catalpol attenuates mptp induced neuronal degeneration of nigralstriatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factoy in striatum. Neuroscience, 2010, 167(1), 174-184.
33. Li, Y.C.; Bao, Y.M.; Jiang, B.; Wang, Z.; Liu, Y.X.; Zhang, C.; An, L.J. Catalpol protects primary cultured astrocytes from in vitro ischemia-induced damage. Int. J. Dev. Neurosci., 2008, 26(3), 309-317.
34. Wang, Z.; An, L.J.; Duan, Y.L.; Li, Y.C.; Jiang, B. Catalpol protects rat pheochromocytoma cells against oxygen and glucose deprivation-induced injury. Neurol. Res., 2008, 30(1), 106-112.
35. Li, D.Q.; Bao, Y.M.; Zhao, J.J.; Liu, C.P.; Ying, L.; An, L.J. Neuroprotective properties of catalpol in transient global cerebral ischemia in gerbils: dose-response, therapeutic time-window and long-term efficacy. Brain Res., 2004, 1029(2), 179-185.
36. Li, D.Q.; Bao, Y.M.; Duan, Y.L.; Liu, C.P.; Ying, L.; An, L.J. Neuroprotection of catalpol in transient global ischemia in gerbils. Neurosc. Res., 2004, 50(2), 169-177.
37. Li, D.Q.; Bao, Y.M.; Liu, Y.X.; Hu, B.; Ying, L.; An, L.J. Catalpol prevents the loss of CA1 hippocampal neurons and reduces working errors in gerbils after ischemia-reperfusion injury. Toxicon., 2005, 46(8), 845-851.
38. Li, D.Q.; Bao, Y.M.; Yang, L.; Wang, C.F.; Liu, Y.X.; An, L.J. Catalpol modulates the expressions of Bcl-2 and Bax and attenuates apoptosis in gerbils after ischemic injury. Brain Res., 2006, 1115, 179-185.
39. Cai, Q.Y.; Chen, X.S.; Zhan, X.L.; Yao, Z.X. Protective effects of catalpol on oligodendrocyte death and myelin breakdown in a rat model of chronic cerebral hypoperfusion. Neurosci. Lett., 2011, 497(1), 22-26.
40. Liu, J.; He, Q.J.; Zou, W.; Wang, H.X.; Bao, Y.M.; Liu, Y.X.; An, L.J. Catalpol increases hippocampal neuroplasticity and upregulates PKC and BDNF in the aged rats. Brain Res., 2006, 1123(1), 68-79.
41. Zhang, X.L.; Jiang, B.; Li, Z.B.; Hao, S.; An, L.J. Catalpol ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. Pharmacol. Biochem. Behav., 2007, 88(1), 64-72.
42. Zhang, X.L.; Zhang, A.H.; Jiang, B.; Bao, Y.M.; Wang, J.Y.; An, L.J. Further pharmacological evidence of the neuroprotective effect of catalpol from Rehmannia glutinosa. Phytomedicine, 2008, 15(6), 484-490.
43. Zhang, X.L.; An, L.J.; Bao, Y.M.; Wang, J.Y.; Jiang, B. Dgalactose administration induces memory loss and energy metabolism disturbance in mice: protective effects of catalpol. Food Chem. Toxicol., 2008, 46(8), 2888-2894.
44. Zhang, X.L.; Liu, W.D.; Niu, X.H.; An, L.J. Systemic administration of catalpol prevents d-galactose induced mitochondrial dysfunction in mice. Neurosci. Lett., 2010, 473(3), 224-228.
45. Jones, R. Neurodegenerative disease: common routes to risk. Nat. Rev. Neurosci., 2013, 14(4), 228-229.
46. Carter, C.J. Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological-signalling cascades. Neurochem. Int., 2008, 52(6), 920-934.
47. Szalardy, L.; Klivenyi, P.; Zadori, D.; Fulop, F.; Toldi, J.; Vecsei, L. Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Cur. Med. Chem., 2012, 19(13), 1899-1920.
48. Orth, M.; Schapira, A.H.V. Mitochondrial involvement in Parkinson's disease. Neurochem. Int., 2002, 40(6), 533-541.
49. Madathil, K.S.; Karuppagounder, S.S.; Haobam, R.; Varghese, M.; Rajamma, U.; Mohanakumar, K.P. Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats. Neurochem. Int., 2013, 62(5), 674-683.
50. Jiang, T.; Zhang, A.H.; Zhao, R.G.; Jiang, B. Protective effect of catalpol in mice injurys induced by rotenone and evaluation of the safty of catalpol. Prog. Modern Biomed., 2008, 8(6), 1039-1045.
51. Gao, H.L.; Li, C.; Nabeka, H.; Shimokawa, T.; Saito, S.; Wang, Z.Y.; Cao, Y.M.; Matsuda, S. Attenuation of MPTP/MPP+ toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin. Neuroscience, 2013, 236, 373-393.
52. Sul, J.W.; Park, M.Y.; Shin, J.; Kim, Y.R.; Yoo, S.E.; Kong, Y.Y.; Kwon, K.S.; Lee, Y.H.; Kim, E. Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration. Hum. Mol. Ggenet., 2013, 22(8), 1558-1573.
53. Sun, X.T.; Liu, J.; Crary, J.F.; Malagelada, C.; Sulzer, D.; Greene, L.A.; Levy, O.A. ATF4 protects against neuronal death in cellular Parkinson's Disease models by maintaining levels of Parkin. J. Neurosci., 2013, 33(6), 2398-2407.
54. Dun, Y.Y.; Yang, Y.; Xiong, Z.G.; Feng, M.; Zhang, Y.; Wang, M.; Xiang, J.Z.; Li, G.; Ma, R. Induction of Dickkopf-1 contributes to the neurotoxicity of MPP+ in PC12 cells via inhibition of the canonical Wnt signaling pathway. Neuropharmacology, 2013, 67, 168-175.
55. Ben-Shlomo, Y.; Bhatia, K. Using monoamine oxidase type B inhibitors in Parkinson's disease: They are effective and safe, at least when used alone. Brit. Med. J., 2004, 329(7466), 581.
56. Facchinetti, F.; Dawson, V.L.; Dawson, T.M. Free radicals as mediators of neuronal injury. Cell. Mol. Neurobiol., 1998, 18(6), 667-682.
57. Hines, D.J.; Haydon, P.G. Inhibition of a SNARE-Sensitive Pathway in Astrocytes Attenuates Damage following Stroke. J. Neurosci., 2013, 33(10), 4234-4240.
58. Liu, G.; Zhao, J.N.; Chang, Z.Y.; Guo, G.D. CaMKII Activates ASK1 to Induce Apoptosis of Spinal Astrocytes Under Oxygen-Glucose Deprivation. Cell. Mol. Neurobiol., 2013, 33(4), 543-549.
59. Wang, D.; Zhao, Y.; Zhang, Y.; Zhang, T.; Shang, X.; Wang, J.; Liu, Y.; Kong, Q.; Sun, B.; Mu, L.; Liu, X.; Wang, G.; Li, H. Hypothermia protects against oxygen-glucose deprivation-induced neuronal injury by down-regulating the reverse transport of glutamate by astrocytes as mediated by neurons. Neuroscience, 2013, 237, 130-138.
60. Griffith, O.W.; Stuehr, D.J. Nitric oxide synthases: properties and catalytic mechanism. Ann. Rev. Physiol., 1995, 57(1), 707-734.
61. Han, Y.F.; Wu, D.C.; Xiao, X.Q.; Chen, P.M.; Chung, W.; Lee, N.T.; Pang, Y.P.; Carlier, P.R. Protection against ischemic injury in primary cultured astrocytes of mouse cerebral cortex by bis-tacrine, a novel anti-Alzheimer's agent. Neurosci. Let., 2000, 288(2), 95-98.
62. Song, X.; Bao, M.M.; Li, D.D.; Li, Y.M. Advanced glycation in Dgalactose induced mouse aging model. Mech. Ageing Dev., 1999, 108(3), 239-251.
63. Tian, J.; Ishibashi, K.; Ishibashi, K.; Reiser, K.; Grebe, R.; Biswal, S.; Gehlbach, P.; Handa, J.T. Advanced glycation endproductinduced aging of the retinal pigment epithelium and choroid: A comprehensive transcriptional response. Proc. Natl. Acad. Sci. USA., 2005, 102(33), 11846-11851.
64. Wei, H.F.; Li, L.; Song, Q.J.; Ai, H.X.; Chu, J.; Li, W. Behavioural study of the D-galactose induced aging model in C57BL/6J mice. Behavioural brain research, 2005, 157(2), 245-251.
65. Dickson.; Dennis, W. The pathogenesis of senile plaques. J. Neuropath Exp. Neur., 1997, 56(4), 321-339.
66. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82(1), 47-95.
67. Opii, W.O.; Joshi, G.; Head, E.; Milgram, N.W.; Muggenburg, B.A.; Klein, J.B.; Pierce, W.M.; Cotman, C.W.; Butterfield, D.A. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol. Aging, 2008, 29(1), 51.
68. Coyle, J.T.; Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative disorders. Science, 1993, 262(5134), 689-695.
69. Floyd, R.A.; Hensley, K. Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging, 2002, 23(5), 795-807.
70. Favilli, F.; Iantomasi, T.; Marraccini, P.; Stio, M.; Lunghi, B.; Treves, C.; Vincenzini, M.T. Relationship between age and GSH metabolism in synaptosomes of rat cerebral cortex. Neurobiol. Aging, 1994, 15(4), 429-433.
71. Jiang, B.; Liu, J.H.; Bao, Y.M.; An, L.J. Catalpol inhibits apoptosis in hydrogen peroxide-induced PC12 cells by preventing cytochrome c release and inactivating of caspase cascade. Toxicon, 2004, 43(1), 53-59.
72. Moncada, S.; Higgs, A.; Furchgott, R. International union of pharmacology nomenclature in nitric oxide research. Pharmacol. Rev., 1997, 49(2), 137-142.
73. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.T.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.F.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging., 2000, 21(3), 383-421.
74. Menzel, R.; Muller, U. Learning and memory in honeybees: from behavior to neural substrates. Annu. Rev. Neurosci., 1996, 19, 379-404.
75. Guix, F.X.; Uribesalgo, I.; Coma, M.; Munoz, F.J. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol., 2005, 76(2), 126-152.
76. Spencer, J.P.E.; Vafeiadou, K.; Williams, R.J.; Vauzour, D. Neuroinflammation: Modulation by flavonoids and mechanisms of action. Mol. Asp. Med., 2012, 33(1), 83-97.
77. Chung, E.S.; Bok, E.; Chung, Y.C.; Baik, H.H.; Jin, B.K. Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase. Brain Res., 2012, 1451, 110-116.
78. Tian, Y.Y.; An, L.J.; Jiang, L.; Duan, Y.L.; Chen, J.; Jiang, B. Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures. Life Sci., 2006, 80(3), 193-199.
79. Itzhak, Y.; Ali, S.F. Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. Pharmacol. Therapeut., 2006, 109(1), 246-262.
80. Mori, K.; Togashi, H.; Ueno, K.I.; Matsumoto, M.; Yoshioka, M. Aminoguanidine prevented the impairment of learning behavior and hippocampal long-term potentiation following transient cerebral ischemia. Behav. Brain Res., 2001, 120(2), 159-168.
81. Raat, N.; Shiva, S.; Gladwin, M. Effects of nitrite on modulating ROS generation following ischemia and reperfusion. Adv. Drug Deliv. Rev., 2009, 61(4), 339-350.
82. Hailer, N.P. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog. Neurobiol., 2008, 84(3), 211-233.
83. Tony, W.C.; Lennart, M. Inflammation in neurodegenerative disease-a double-edged sword. Neuron, 2002, 35(3), 419-432.
84. Wu, X.F.; Block, M.L.; Zhang, W.; Qin, L.; Wilson, B.; Zhang, W.Q.; Veronesi, B.; Hong, J.S. The role of microglia in paraquatinduced dopaminergic neurotoxicity. Antioxid. Redox. Sign., 2005, 7(5-6), 654-661.
85. Gao, H.M.; Hong, J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol., 2008, 29(8), 357-365.
86. Frauke, Z.; Orhan, A. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci., 2006, 29(9), 518-527.
87. Yenari, M.A.; Xu, L.J.; Tang, X.N.; Qiao, Y.L.; Giffard, R.G. Microglia potentiate damage to blood-brain barrier constituents-Improvement by minocycline in vivo and in vitro. Stroke, 2006, 37(4), 1087-1093.
88. Block, M.L.; Hong, J.S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog. Neurobiol., 2005, 76(2), 77-98.
89. Zhang, A.; Hao, S.; Bi, J.; Bao, Y.; Zhang, X.; An, L.; Jiang, B. Effects of catalpol on mitochondrial function and working memory in mice after lipopolysaccharide-induced acute systemic inflammation. Exp. Toxicol. Pathol., 2009, 61(5), 461-469.
90. Hertz, L.; Zielke, H.R. Astrocytic control of glutamatergic activity: Astrocytes as stars of the show. Trends Neurosci., 2004, 27(12), 735-743.
91. Bernhardi, R.V.; Eugenin, J. Microglia reactivity to -amyloid is modulated by astrocytes and proinflammatory factors. Brain Res., 2004, 1025, 186-193.
92. Bi, J.; Jiang, B.; Liu, J.H.; Lei, C.; Zhang, X.L.; An, L.J. Protective effects of catalpol against H2O2-induced oxidative stress in astrocytes primary cultures. Neurosci. Lett., 2008, 442(3), 224-227.
93. Bi, J.; Jiang, B.; Zorn, A.; Zhao, R.G.; Liu, P.; An, L.J. Catalpol inhibits LPS plus IFN-induced inflammatory response in astrocytes primary cultures. Toxicol. in Vitro, 2013, 27(2), 543-550.
94. Ridder, D.A.; Schwaninger, M. In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease. Exp. Neuro., 2012, 238(2), 133-137.
95. Qiao, H.J.; Koya, R.C.; Nakagawa, K.; Tanaka, H.; Fujita, H.; Takitmoto, M.; Kuzamaki, N. Inhibition of Alzheimer'amyloidpeptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol. Aging, 2005, 26, 849-855.
96. Martinou, J.C.; Youle, R.J. Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial Dynamics. Dev. Cell, 2011, 21(1), 92-101.
97. Gonzalez, F.F.; Ferriero, D.M. Therapeutics for neonatal brain injury. Pharmacol. Ther., 2008, 120(1), 43-53.
98. Reed, J.C. Apoptosis-based therapies. Nat. Rev. Drug Discov., 2002, 1(2), 111-121.
99. Krantic, S.; Mechawar, N.; Reix, S.; Quirion, R. Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci., 2005, 28(12), 670-676.
100. Dlamini, Z.; Mbita, Z.; Zungu, M. Genealogy, expression, and molecular mechanisms in apoptosis. Pharmacol. Ther., 2004, 101(1), 1-15.
101. Wang, Z.; An, L.J.; Duan, Y.L.; Li, Y.C., Jang, B. Catalpol Protects Rats' Pheochromocytoma Cells Against Oxygen-glucose Deprivation-induced Injury. Prog. Modern Biomed., 2006, 12, 12-15.
102. Oneill, L.A.J.; Kaltschmidt, C. NF-kappa B: A crucial transcription factor for glial and neuronal cell function. Trends Neurosci., 1997, 20(6), 252-258.
103. Nelson, D.E.; Ihekwaba, A.E.; Elliott, M.; Johnson J.R. Oscillations in NF-B signaling control the dynamics of gene expression. Science, 2004, 306, 704-708.
104. Adler, A.S.; Sinha, S.; Kawahara, T.L.; Zhang, J.Y.; Segal, E.; Chang, H.Y. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev., 2007, 21, 3244-3257.
105. Meffert, M.K.; Baltimore, D. Physiological functions for brain NFkB. Trends Neurosci., 2005, 28(1), 37-43.
106. Marco, C.; Tiziana, P. Nitric oxide: An inhibitor of NF-B/Rel system in glial cells. Brain Res. Bull., 2000, 52(3), 155-161.
107. Komatsubara, A.T.; Asano, T.; Tsumoto, H.; Shimizu, K.; Nishiuchi, T.; Yoshizumi, M.; Ozawa, K. Proteomic analysis of Snitrosylation induced by 1-methyl-4-phenylpyridinium (MPP+). Proteome Sci., 2012, 10(1), 74.
108. Pope, S.; Land, J.M.; Heales, S.J. Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target? Biochim. Biophys. Acta, 2008, 1777(7), 794-799.
109. Matthews, J.R.; Botting, C.H.; Panico, M.; Morris, H.R.; Hay, R.T. Inhibition of NF-B DNA binding by nitric oxide. Nucl. Acids Res., 1996, 24(12), 2236-2242.
110. Murer, M.;Yan, Q.; Raisman-Vozari, R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol., 2001, 63(1),71-124.
111. Dawson, T.M.; Dawson, V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci., 2002, 5, 1058-1061.
112. Lau, Y.S.; Patki, G.; Das-Panja, K.; Le, W.D.; Ahmad, S.O. Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration. Eur. J. Neurosci., 2011, 33(7),1264-1274.
113. Wu, S.Y.;Wang, T.F.;Yu, L.;Jen, C.J.;Chuang, J.I.;Wu, F.S.;Wu, C.W.;Kuo, Y.M. Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. Brain Behav. Immun., 2011, 25(1), 135-146.
114. Yang, X.; Mertens, B.; Lehtonen, E.;Vercammen, L.; Bockstael, O.; Chtarto, A.; Levivier, M.; Brotchi, J.; Michotte, Y.; Baekelandt, V. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. J. Gene Med., 2009, 11(10), 899-912.
115. Cao, J.J.; Li, K.S.; Shen, Y.Q. Activated Immune Cells in Parkinson's Disease. J. Neuroimm. Pharm., 2011, 6(3),323-329.
116. Nagahara, A.H.;Tuszynski, M.H; Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov., 2011, 10(3), 209-219.
117. Allaman, I.; Fiumelli, H.; Magistretti, P.J.; Martin, J.L. Fluoxetine regulates the expression of neurotrophic growth factors and glucose metabolism in astrocytes. Psychopharmacology, 2011, 216(1), 75-84.
118. Poon, W.W.; Blurton-Jones, M.; Tu, C.H.; Feinberg, L.M.; Chabrier, M.A.; Harris, J.W.; Jeon, N.L.; Cotman, C.W. beta-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol. Aging, 2011, 32(5), 821-833.
119. Castillo, P.E.; Chiu, C.Y.Q.; Carroll, R.C. Long-term plasticity at inhibitory synapses. Curr. Opin. Neurobiol., 2011, 21(2), 328-338.
120. Covington, H.E.; Maze, I.;Sun, H.S.; Bomze, H.M.; DeMaio, K.D.; Wu, E.Y.; Dietz, D.M.; Lobo, M.K.; Ghose, S.; Mouzon, E.; Neve, R.L.; Tamminga, C.A.; Nestler, E.J. A Role for Repressive Histone Methylation in Cocaine-Induced Vulnerability to Stress. Neuron, 2011, 71(4), 656-670.
121. Zeng, Y.; Tan, M.; Kohyama, J.; Sneddon, M.;Watson, J.B.; Sun, Y.E.; Xie, C.W. Epigenetic Enhancement of BDNF Signaling Rescues Synaptic Plasticity in Aging. J. Neurosci., 2011, 31(49),17800-17810.
122. Dieni, S.; Matsumoto, T.; Dekkers, M.; Rauskolb, S.; Ionescu, M.S.; Deogracias, R.; Gundelfinger, E.D.; Kojima, M.; Nestel, S.; Frotscher, M.; Barde, Y.A. BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. J. Cell Biol., 2012, 196(6) , 775-788.
123. Stansfield, K.H.; Pilsner, J.R.; Lu, Q.; Wright, R.O.; Guilarte, T.R. Dysregulation of BDNF-TrkB Signaling in Developing Hippocampal Neurons by Pb2+: Implications for an Environmental Basis of Neurodevelopmental Disorders. Toxicol. Sci., 2012, 127(1), 277-295.
124. Adler, A.S.; Sinha, S.; Kawahara, T.L.A.; Zhang, J.Y.; Segal, E., Chang, H.Y. Motif module map reveals enforcement of aging by continual NF-kappa B activity. Genes Dev., 2007, 21(24), 3244-3257.
125. Burger, S.; Doring, B.; Hardt, M.; Beuerlein, K.;Gerstberger, R.;Geyer, J. Co-expression studies of the orphan carrier protein Slc10a4 and the vesicular carriers VaChT and VMAT2 in the rat central and peripheral nervous system. Neuroscience, 2011, 193,109-121.
126. Zylbersztejn, K.; Petkovic, M.; Burgo, A.; Deck, M.; Garel, S.; Marcos, S.; Bloch-Gallego, E.; Nothias, F.; Serini, G.; Bagnard, D.; Binz, T.; Galli, T. The vesicular SNARE Synaptobrevin is required for Semaphorin 3A axonal repulsion. J. Cell Biol., 2012, 196(1), 37-46.
127. Blurton-Jones, M.; Kitazawa, M.; Martinez-Coria, H.; Castello, N.A.; Muller, F.J.; Loring, J.F.;Yamasaki, T.R.;Poon, W.W.;Green, K.N.;LaFerla, F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci., 2009, 106(32),13594-13599.
128. Erickson, K.I.; Prakash, R.S.;Voss, M.W.; Chaddock, L.; Heo, S.; McLaren, M.; Pence, B.D.; Martin, S.A.; Vieira, V.J.; Woods, J.A. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J. Neurosci., 2010, 30(15), 5368-5375.
129. Price, R.D.;Milne, S.A.;Sharkey, J.;Matsuoka, N. Advances in small molecules promoting neurotrophic function. Pharmacol. Therapeut., 2007, 115(2), 292-306.
130. Zhu, H.F.; Wan, D.; Luo, Y.; Xie, P.; Xu, X.Y. Catalpol upregulated GAP-43 protein expression and improved behavior outcome of focal cerebral ischemia rats. Chin. Pharmacol. Bull., 2007, 23(9),1231.
131. Wan, D.; Zhu, H.F.; Luo, Y.; Xie, P.; Xu, X.Y. Study of catalpol promoting axonal growth for cultured cortical neurons from rats. Chin. J. Chin. Mater. Med., 2007, 32(17), 1771.
132. He, X.; Sandhu, H.K.; Yang, Y.; Hua, F.; Belser, N.; Kim, D.H.; Xia, Y. Neuroprotection against hypoxia/ischemia: -opioid receptor-mediated cellular/molecular events. Cell Mol. Life Sci., 2013, 70(13), 2291-2303.
133. Chao, D.; He, X.; Yang, Y.; Bazzy-Asaad, A.; Lazarus, L.H.; Balboni, G.; Kim, D.H., Xia, Y. DOR activation inhibits anoxic/ischemic Na+ influx through Na+ channels via PKC mechanisms in the cortex. Exp. Neurol., 2012, 236, 228-239.
134. Chao, D.; Xia, Y. Ionic storm in hypoxic/ischemic stress: can opioid receptors subside it? Prog. Neurobiol., 2010, 90(4), 439-470.
135. Ma, M.C.; Qian,H.; Ghassemi, F.; Zhao, P.; Xia, Y. Oxygensensitive delta-opioid receptor-regulated survival and death signals-Novel insights into neuronal preconditioning and protection. J. Biol. Chem., 2005, 280(16),16208-16218.
136. Carlos, R.P.; Leticia, G, L.; Celina, G.;Victor, S.; Carlos E.; .Jose, M. Novel antiproliferative analogs of the Taq DNA polymerase inhibitor catalpol. Bioorg. Med. Chem. Lett., 2007, 17(5), 1332-1335.
137. Gutierrez, R.M.P.;Solis, R.V.;Baez, E.G.;Martinez, F.M. Effect on capillary permeability in rabbits of iridoids from Buddleia scordioides. Phytother. Res., 2006, 20(7), 542-545.
138. Ke, Y.F. Antihyperglycemic action of catalpol.; National Cheng Kung University: Taibei, 2003.
139. Wang, Q.; Xing, M.; Chen, W.; Zhang, J.; Qi, H.; Xu, X. HPLC-APCI-MS/MS method for the determination of catalpol in rat plasma and cerebrospinal fluid: Application to an in vivo pharmacokinetic study. J. Pharmaceut. Biomed., 2012, 70, 337-343.
140. Lu R; Gu Y; Si D.Y.; Xiao, L.C. Quantitation of catalpol in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry and its pharmacokinetic study. J. Chromatogr. B., 2009, 877(29), 3589-3594.